nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2015 | short review

The role of positron emission tomography in breast cancer: a short review

verfasst von: Maria Adele Marino, MD, Univ. Prof. Thomas H. Helbich, MD, MSc, MBA, Univ. Prof. Alfredo Blandino, MD, Assoc. Prof. Katja Pinker, MD, EBBI

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Positron emission tomography (PET) provides information about abnormal metabolic features associated with cancer, and its role in breast cancer has been widely investigated. In the past several years, combined imaging systems, such as PET/CT and PET/MRI, and dedicated breast PET devices, such as PEM and MAMMI-PET, have been developed and implemented. These new techniques have become an effective oncologic tool for staging, re-staging, monitoring response to treatment, and estimation of the long-term prognosis. The aim of this review is to summarize the established and emerging PET imaging techniques and to discuss their value in the management of breast cancer patients.

Vorheriger Artikel The relevance of positron emission tomography response in non-small cell lung cancer

Nächster Artikel Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival

Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26:779–86. doi:10.1093/annonc/mdv001.

Bosetti C, Bertuccio P, Levi F, et al. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21:77–82.PubMedCrossRef

Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136–222.PubMed

Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296–316.PubMedCrossRef

Pinker K, Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, et al. Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging. Invest Radiol. 2014;49(6):421–30.PubMedCrossRef

Pinker K, Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P, et al. Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study. Clin Cancer Res. 2014;20(13):3540–9. doi:10.1158/1078-0432.CCR-13-2810.

Baltzer PA, Dietzel M. Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T—systematic review and meta-analysis. Radiology. 2013;267(3):735–46.

Kong EJ, Chun KA, Bom HS, Lee J, Lee SJ, Cho IH. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma. Hell J Nucl Med. 2014;17(3):171–6.PubMed

Warburg O. Metabolism of tumors. London:constable and Company; 1930.

10.

Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266(2):388–405. doi:10.1148/radiol.12110853.

11.

Avril N, Rosé CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495–502.PubMed

12.

Kalles V, Zografos GC, Provatopoulou X, et al. The current status of positron emission mammography in breast cancer. Breast Cancer. 2013;20(2):123–30.PubMedCrossRef

13.

Yoon H, Kang KW, Chun IK, Cho N, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesteron receptor, and HER2 with functional imaging parameters from 68GA-RDG PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534–43.PubMedCrossRef

14.

Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440–6.PubMed

15.

Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–85.PubMedCrossRef

16.

Berg WA, Madsen KS, Schilling K, et al. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol. 2012;198:219–32.PubMedCrossRef

17.

Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, et al. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012;83:1381–6.PubMedCrossRef

18.

Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emmision tomography. Acta Radiol. 2011;52(1):21–8.

19.

Tatsumi M, Cohade C, Mourtzikos KA, et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33(3):254–62.PubMedCrossRef

20.

Rosen EL, Eubank W, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–29.

21.

Magometschnigg HF, Helbich TH, Brader P, et al. Molecular imaging for the characterization of breast tumours. Expert Rev Anticancer Ther. 2014;14(6):711–22.PubMedCrossRef

22.

Choi YJ, Shin YD, Kang YH, et al. The effects of preoperative (18)F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study. J Breast Cancer. 2012;15(4):441–8.PubMedCentralPubMedCrossRef

23.

Taneja S, Jena A, Goel R, Sarin R, et al. Simultaneous whole-body 18F-FDG PET/MRI in primary staging of breast cancer: a pilot study. Eur J Radiol. 2014;83:2231–9.PubMedCrossRef

24.

Pinker K, Bickel H, Magometschnigg H, et al. Molecular imaging of breast tumours with PET/MRI—proof of concept. 6th EMIM. 2011;8:92.

25.

Eo JS, Chun IK, Paeng JC, et al. Imaging sensitivity of dedicated positron emission mammography in relation to tumour size. Breast. 2012;21(1):66–71. doi:10.1016/j.breast.2011.08.002. Epub 2011 Aug 25.PubMedCrossRef

26.

Mankoff DA, Sprecht JM. [18F]Fluorodeoxyglucose positron emission tomography—computed tomography in breast cancer: when… and when not? J Clin Oncol. 2012;30(12):1252–4.PubMedCrossRef

27.

Koolen BB, Vogel WV, Vrancken Peeters MJTFD, et al. Molecular imaging in breast cancer: from whole-body PET/CT to dedicated breast PET. J Oncol. 2012. doi:10.1155/2012/438647.

28.

Riedl CC, Slobod E, Jochelson M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55(10):1578–83.PubMedCentralPubMedCrossRef

Titel: The role of positron emission tomography in breast cancer: a short review
verfasst von: Maria Adele Marino, MD
Univ. Prof. Thomas H. Helbich, MD, MSc, MBA
Univ. Prof. Alfredo Blandino, MD
Assoc. Prof. Katja Pinker, MD, EBBI
Publikationsdatum: 01.06.2015
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-015-0210-z

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Amino acid PET monitoring in gliomas

Cytomegalovirus retinitis in a child with lymphoblastic lymphoma

The relevance of positron emission tomography response in non-small cell lung cancer

Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival

PET/CT in management of oncologic patients

Esthesioneuroblastoma metastatic to the neck and lung: a case report and review of the literature